Current Challenges to the United States’ AIDS Drug Assistance Program and Possible Implications of the Affordable Care Act
AIDS Drug Assistance Programs, enacted through the Ryan White Comprehensive AIDS Resources Emergency Act of 1990, are the “payer of last resort” for prescription medications for lower income, uninsured, or underinsured people living with HIV/AIDS. ADAPs face declining funding from the federal govern...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | AIDS Research and Treatment |
| Online Access: | http://dx.doi.org/10.1155/2013/350169 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524648244674560 |
|---|---|
| author | Kathleen A. McManus Carolyn L. Engelhard Rebecca Dillingham |
| author_facet | Kathleen A. McManus Carolyn L. Engelhard Rebecca Dillingham |
| author_sort | Kathleen A. McManus |
| collection | DOAJ |
| description | AIDS Drug Assistance Programs, enacted through the Ryan White Comprehensive AIDS Resources Emergency Act of 1990, are the “payer of last resort” for prescription medications for lower income, uninsured, or underinsured people living with HIV/AIDS. ADAPs face declining funding from the federal government. State funding of ADAP is discretionary, but some states increased their contributions to meet the gap in funding. The demand for ADAP support is increasing as people living with HIV are living longer; the antiretroviral therapy (ART) guidelines have been changed to recommend initiation of treatment for all; the United States is increasing HIV testing goals; and the recession continues. In the setting of increased demand and limited funding, ADAPs are employing cost containment measures. Since 2010, emergency federal funds have bailed out ADAP, but these are not sustainable. In the coming years, providers and policy makers associated with HIV care will need to navigate the implementation of the Affordable Care Act (ACA). Lessons learned from the challenges associated with providing sustainable access to ART for vulnerable populations through ADAP should inform upcoming decisions about how to ensure delivery of ART during and after the implementation of the ACA. |
| format | Article |
| id | doaj-art-91dae1f263e5409dbf4a766e32c9ab05 |
| institution | Kabale University |
| issn | 2090-1240 2090-1259 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | AIDS Research and Treatment |
| spelling | doaj-art-91dae1f263e5409dbf4a766e32c9ab052025-02-03T05:47:49ZengWileyAIDS Research and Treatment2090-12402090-12592013-01-01201310.1155/2013/350169350169Current Challenges to the United States’ AIDS Drug Assistance Program and Possible Implications of the Affordable Care ActKathleen A. McManus0Carolyn L. Engelhard1Rebecca Dillingham2Department of Medicine, University of Virginia, Charlottesville, VA 22903, USADepartment of Public Health Sciences, University of Virginia, Charlottesville, VA 22908-0717, USADivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia, P.O. Box 801379, Charlottesville, VA 22908, USAAIDS Drug Assistance Programs, enacted through the Ryan White Comprehensive AIDS Resources Emergency Act of 1990, are the “payer of last resort” for prescription medications for lower income, uninsured, or underinsured people living with HIV/AIDS. ADAPs face declining funding from the federal government. State funding of ADAP is discretionary, but some states increased their contributions to meet the gap in funding. The demand for ADAP support is increasing as people living with HIV are living longer; the antiretroviral therapy (ART) guidelines have been changed to recommend initiation of treatment for all; the United States is increasing HIV testing goals; and the recession continues. In the setting of increased demand and limited funding, ADAPs are employing cost containment measures. Since 2010, emergency federal funds have bailed out ADAP, but these are not sustainable. In the coming years, providers and policy makers associated with HIV care will need to navigate the implementation of the Affordable Care Act (ACA). Lessons learned from the challenges associated with providing sustainable access to ART for vulnerable populations through ADAP should inform upcoming decisions about how to ensure delivery of ART during and after the implementation of the ACA.http://dx.doi.org/10.1155/2013/350169 |
| spellingShingle | Kathleen A. McManus Carolyn L. Engelhard Rebecca Dillingham Current Challenges to the United States’ AIDS Drug Assistance Program and Possible Implications of the Affordable Care Act AIDS Research and Treatment |
| title | Current Challenges to the United States’ AIDS Drug Assistance Program and Possible Implications of the Affordable Care Act |
| title_full | Current Challenges to the United States’ AIDS Drug Assistance Program and Possible Implications of the Affordable Care Act |
| title_fullStr | Current Challenges to the United States’ AIDS Drug Assistance Program and Possible Implications of the Affordable Care Act |
| title_full_unstemmed | Current Challenges to the United States’ AIDS Drug Assistance Program and Possible Implications of the Affordable Care Act |
| title_short | Current Challenges to the United States’ AIDS Drug Assistance Program and Possible Implications of the Affordable Care Act |
| title_sort | current challenges to the united states aids drug assistance program and possible implications of the affordable care act |
| url | http://dx.doi.org/10.1155/2013/350169 |
| work_keys_str_mv | AT kathleenamcmanus currentchallengestotheunitedstatesaidsdrugassistanceprogramandpossibleimplicationsoftheaffordablecareact AT carolynlengelhard currentchallengestotheunitedstatesaidsdrugassistanceprogramandpossibleimplicationsoftheaffordablecareact AT rebeccadillingham currentchallengestotheunitedstatesaidsdrugassistanceprogramandpossibleimplicationsoftheaffordablecareact |